Pol F. Boudes - Jan 24, 2022 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Role
Chief Medical Officer
Signature
Jack W. Callicutt, by power of attorney
Stock symbol
GALT
Transactions as of
Jan 24, 2022
Transactions value $
$0
Form type
4
Date filed
1/25/2022, 03:17 PM
Next filing
Sep 9, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GALT Stock Option (right to buy) Award $0 +50K $0.00 50K Jan 24, 2022 Common Stock 50K $1.98 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan.
F2 The options vest as follows: 25% on each of June 30, 2022; December 31, 2022; June 30, 2023; and December 31, 2023.